

Financial Tear Sheet

Company Overview

LivaNova is a global medical technology company built on nearly five decades of experience and a relentless commitment to improve the lives of patients around the world. Our advanced technologies and breakthrough treatments provide meaningful solutions for the benefit of patients, healthcare professionals and healthcare systems.

At LivaNova, we understand the importance of bringing both clinical and economic value to our customers. We are a strong, market-leading medical technology and services company, offering a diverse product portfolio and global reach. LivaNova is listed on the NASDAQ stock exchange and London Stock Exchange (LSE) under the ticker symbol "LIVN."

LivaNova is a market leader with a workforce of approximately 4,500 employees worldwide. We are headquartered in London (UK) and maintain a presence in more than 100 countries. LivaNova operates as three business franchises:

- **Cardiac Surgery:** We are a global leader in cardiac surgery based on many factors, including our established leadership position in heart-lung machines and recognition as the world's #1 cardiopulmonary bypass company. Our advanced solutions have made significant contributions to open-heart surgery outcomes for many patients. Notably, we offer the only sutureless valve for aortic surgery.
- **Neuromodulation:** As pioneers of the VNS (Vagus Nerve Stimulation) Therapy[®] system, we continue to advance medical device solutions for people affected by treatment-resistant epilepsy, depression, heart failure and other chronic disorders.
- **Cardiac Rhythm Management:** Reflecting our spirit of imagination and invention, we have a long history of designing cardiac rhythm management systems, including pacemakers and defibrillators, that enhance and extend lives.

At LivaNova, we serve health and improve lives. Day by day. Life by life.

Stock Information

LIVN:NDAQ

LIVN:LSE

Exchange NASDAQ GS (US Dollar)

Price \$74.82

Change (%) ▲ 0.60 (0.81%)

Volume 315,305

Data as of 10/20/17 4:00 p.m. ET
Minimum 15 minutes delayed.

Latest News

OCT 09, 2017

LivaNova Receives FDA Approvals for SenTiva Device and Next-Generation VNS Therapy Programming System for Treatment of Epilepsy

OCT 02, 2017

LivaNova Announces One-Millionth Patient Treated with Advanced XTRA Autotransfusion System

SEP 28, 2017

LivaNova to Host Conference Call for Third Quarter 2017 Results

Upcoming Events

NOV 02, 2017 8:00 A.M. CT

Q3 2017 LivaNova PLC Earnings Conference Call

SEP 20, 2017 9:30 A.M. UKT

2017 LivaNova PLC Investor Day London

SEP 14, 2017 9:00 A.M.

THROUGH

09/14/17 2:30 P.M. ET

2017 LivaNova PLC Investor Day NYC

Quarterly Results

MAR 01, 2017

LivaNova Reports Fourth Quarter and Full-Year 2016 Results

MAR 01, 2017

Q4 and Full Year 2016 LivaNova PLC Earnings Conference Call

MAR 01, 2017

10-K Annual report which provides a comprehensive overview of the company for the past year

SEC Filings

Filing Date	Form
10/17/17	4
09/19/17	4
09/14/17	8-K
08/17/17	4